Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

23 Nov 2020 08:59

RNS Number : 1549G
GlaxoSmithKline PLC
23 November 2020
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

135,376

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

74,556

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

60,820

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

254,091

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

32,278

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

221,813

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - ADS

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

4,692,680

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

64,816

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

4,627,864

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

1,447,405

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

169,776

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,277,629

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRKZMZMRFRGGZG
Date   Source Headline
28th Feb 202211:00 amRNSGSK introduces Haleon to investors
28th Feb 20227:00 amRNSGSK RSV maternal vaccine candidate further update
24th Feb 20224:22 pmRNSDirector/PDMR Shareholding
24th Feb 20223:12 pmRNSCanada Approval For Medicago GSK Covid-19 Vaccine
23rd Feb 20222:50 pmRNSDirector/PDMR Shareholding
22nd Feb 20222:00 pmRNSGSK Consumer Healthcare to be called Haleon
22nd Feb 20229:22 amRNSDirector/PDMR Shareholding
18th Feb 20224:30 pmRNSDirector/PDMR Shareholding
18th Feb 20227:00 amRNSGSK gives update on RSV maternal vaccine candidate
17th Feb 20224:00 pmRNSDirector/PDMR Shareholding
17th Feb 20223:40 pmRNSDirector/PDMR Shareholding
17th Feb 20223:20 pmRNSDirector/PDMR Shareholding
17th Feb 20222:50 pmRNSDirector/PDMR Shareholding
17th Feb 20222:19 pmRNSDirector/PDMR Shareholding
16th Feb 20226:04 pmRNSDirector/PDMR Shareholding
14th Feb 20225:50 pmRNSDirector/PDMR Shareholding
14th Feb 20221:26 pmRNSTransfer of Treasury Shares
11th Feb 20222:06 pmRNSDirector/PDMR Shareholding
11th Feb 20229:33 amRNSDirector/PDMR Shareholding
10th Feb 20229:00 amRNSBenlysta approved in China for Lupus Nephritis
9th Feb 202211:07 amRNSDirector/PDMR Shareholding
9th Feb 20227:00 amRNSFinal Results
7th Feb 202210:30 amRNSPublication of full year 2021 results: Replacement
7th Feb 202210:00 amRNSPublication of full year 2021 results
2nd Feb 20227:00 amRNSGSK announces settlement between ViiV and Gilead
1st Feb 20221:44 pmRNSFDA approves ViiV Healthcare’s sNDA for Cabenuva
1st Feb 202211:44 amRNSTotal Voting Rights
26th Jan 20224:48 pmRNSDirector/PDMR Shareholding
20th Jan 20223:59 pmRNSDirector/PDMR Shareholding
19th Jan 20224:33 pmRNSDirector/PDMR Shareholding
19th Jan 20223:14 pmRNSDirector/PDMR Shareholding
19th Jan 20223:10 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSTony Wood appointed CSO Designate, GSK
17th Jan 20225:04 pmRNSDirector/PDMR Shareholding
17th Jan 20223:07 pmRNSDirector/PDMR Shareholding
17th Jan 20227:00 amRNSUpdate - GSK Consumer Healthcare
14th Jan 20223:22 pmRNSDirector/PDMR Shareholding
13th Jan 20224:12 pmRNSDirector/PDMR Shareholding
11th Jan 20224:28 pmRNSDirector/PDMR Shareholding
11th Jan 202212:08 pmRNSUS Govt buys additional 600,000 sotrovimab doses
4th Jan 202212:28 pmRNSTotal Voting Rights
23rd Dec 20211:11 pmRNSDirector/PDMR Shareholding
22nd Dec 20212:57 pmRNSDirector/PDMR Shareholding
21st Dec 20217:00 amRNSViiV Healthcare announces FDA approval of Apretude
20th Dec 20217:00 amRNSConsumer Healthcare Chair Designate appointed
17th Dec 202112:48 pmRNSXevudy approved in Europe to treat COVID-19
15th Dec 20217:00 amRNSGSK/Sanofi COVID-19 vaccine booster & Ph3 update
13th Dec 202111:25 amRNSDirector/PDMR Shareholding
9th Dec 20214:35 pmRNSDirector/PDMR Shareholding
7th Dec 202112:00 pmRNSMedicago/GSK COVID-19 vaccine positive Ph3 data

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.